Stock market news

DuPont de Nemours

DuPont announced the termination of its agreement to acquire Rogers Corporation because the companies failed to obtain timely approval from all necessary regulatory agencies. DuPont will pay Rogers $162.5 million in compensation.

Rogers

DuPont announced the termination of its agreement to acquire Rogers Corporation because the companies failed to obtain timely approval from all necessary regulatory agencies. DuPont will pay Rogers $162.5 million in compensation.

Sprague Resources

Hartree Partners completed its acquisition of Sprague Resources at $19 per unit.

MERIDIAN

MERIDIAN's RAS net income for 9 months of 2022 was ₽98.456 million, compared to a loss of ₽8.619 million in the previous year.

Far-Eastern Shipping Company

FESCO's RAS net profit for 9 months of 2022 was ₽1.838 billion, up 12 times from ₽0.15 billion in the previous year. Revenue doubled to ₽5.73 billion versus ₽2.89 billion a year earlier.

KAMAZ

Automobile Concern Kamaz completes the test operation of passenger transportation on demand Chelnok. In November it will start operating in normal mode. This is a hybrid service of public transport and cabs, which allows passengers to order and pay for rides through the app, and get from the ordering point to the drop-off point without transferring. The serv...

Levenhuk

Levenguc's board of directors has recommended a dividend of not more than ₽20.1 million for the first nine months of 2022. On a per share basis, the maximum dividend is ₽0.379 per common share. The dividend yield could be as high as 2.8%. The last day to purchase securities for the dividend and the exact amount of the payout will be determined at the Novembe...

Simon Property Group

Simon Property Group's funds from operations for 9 months of 2022 were $3.207 billion, down 3.6% from $3.327 billion in the previous year. Revenue increased 3% to $3.618 billion from $3.512 billion a year earlier.

Aerojet Rocketdyne Holdings

Aerojet Rocketdyne's GAAP net income for 9 months of 2022 was $57.9 million, down 45.2% from $105.6 million in the previous year. Revenue declined 0.5% to $1.588 billion from $1.596 billion a year earlier.

ABIOMED

Johnson & Johnson is buying Abiomed for $16.6 billion, or $380 per share. Abiomed shareholders will also be entitled to another $35.00 per share if certain commercial and clinical milestones are met. Transaction is expected to close in the first quarter of 2023.